Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...

and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as a company almost 10 years, which many people don ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... She founded ARK Investment Management around ten years ago and has over three decades of experience in ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...